Physician profile
Jonathan Shader
NPI 1689038986
$1,993.31
in general payments reported to CMS, 2019-2025
13 companies · $295 in 2025
The $295 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $22.42 · 2021: $268 · 2022: $177 · 2023: $253 · 2024: $765 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104 · Charitable Contribution: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.77 |
| Charitable Contribution | $209.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $685.51 | 2019-2025 | Clareon, Luxor |
| Bausch & Lomb Americas INC. | $299.37 | 2022-2025 | Miebo, Xiidra, Envista Envy Iol |
| Microsurgical Technology, INC. | $209.63 | 2024 | |
| Rxsight INC | $144.66 | 2025 | Rxsight Injector Cartridge, Light Adjustable Lens (Lal), Rxsight Contact Lens |
| Amgen INC. | $123.13 | 2024 | Krystexxa |
| Horizon Therapeutics Plc | $119.37 | 2022 | |
| Allergan, INC. | $99.99 | 2019 | |
| Mallinckrodt Hospital Products INC. | $81.36 | 2021 | |
| Boston Scientific Corporation | $72.27 | 2025 | General - Pain Management |
| Glaukos Corporation | $66.73 | 2019-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Harrow Eye, LLC | $31.57 | 2025 | Iheezo, Vevye |
| Carl Zeiss Meditec USA, INC. | $31.52 | 2022 | |
| Lombart Brothers, INC. | $28.20 | 2024 | Opd-III |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Shader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.